The manufacturing licensing expands Tilray’s international export capacity to include the authorized manufacturing of products from medical cannabis flowers and cannabis oil. Tilray is also authorized to export Portuguese end products to international markets. Tilray’s EU campus in Portugal is a versatile production site with outdoor and greenhouse cultivation and a center for clinical research.
Tilray Inc., a global pioneer in the discovery, cultivation, production, and distribution of cannabis, just announced that its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. has obtained a Good Manufacturing Practice (GMP) certification in accordance with European Union standards for its production facility in Cantanhede, Portugal.
Tilray Inc. to produce GMP-certified medical cannabis end products
The GMP certification to Tilray Inc. was granted by Infarmed, the Portuguese regulatory authority for medicine and medical supplies.
This second GMP certification allows Tilray Inc. Portugal to manufacture GMP-certified medical cannabis end products, including dried flowers and oils, and distribute them from Portugal to international markets in accordance with the legal requirements for medical cannabis.
“We are delighted with the continued momentum of our growth strategy across Europe, which is supported by this additional GMP certification for Tilray Inc.’s EU campus in Portugal,” said Brendan Kennedy, Tilray Inc. CEO.
“Thanks to the certification, we can now export a wider range of medical devices for international patients, partners, and markets. Our international strategy is an important factor in increasing our profitability and long-term value to our shareholders.”
Tilray Inc.’s EU campus
Tilray Inc.’s EU campus in Portugal is a versatile production site with outdoor and greenhouse cultivation, research and quality assurance laboratories as well as processing, packaging and distribution sites for medical cannabis.
In addition, the EU Campus serves as a center for Tilray’s Europe-wide clinical research and product development activities. The company expected several harvests in the coming months.
In May 2019, Tilray Inc. Portugal received a manufacturing license and its first GMP certification, allowing it to produce large quantities of dried cannabis and export the active substances as raw materials.
In September 2019 Tilray Inc. Portugal carried out the first export to Germany and thus to this day the first intra-European mass supply of medical cannabis. The additional GMP certification enables Tilray Inc. to supply international markets with pharmaceutical dried flowers and oils as medical cannabis end products.
Tilray’s pharmaceutical-grade medical cannabis products
“We now have two GMP-certified facilities to support our global expansion strategy,” said Sascha Mielcarek, Tilray Managing Director in Europe. “We are delighted to have the opportunity to distribute our leading medical cannabis flower and oil products to international markets. We will continue to expand our presence to provide patients with access to Tilray’s pharmaceutical-grade medical cannabis products made in Europe.”
Tilray Inc. has already entered into sales and distribution agreements to supply medical cannabis via the main pharmaceutical distribution channels in Germany and other European countries.
These agreements give affected patients access to Tilray’s final medical cannabis products.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in BusinessWire, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.